Vyome Holdings (HIND) Price to Sales (2025 - 2026)

Vyome Holdings (HIND) posted Price to Sales of 559.82 for Q2 2026, up 17.2% on a QoQ basis from 477.66 in Q1 2026.

Analysis

Vyome Holdings (HIND) Price to Sales (2025 - 2026) Analysis & Trends

Vyome Holdings has reported Price to Sales for 2 years, with the latest figure at 559.82 in Q2 2026.

On a quarterly basis, Price to Sales changed N/A year-over-year to 559.82 in Q2 2026; TTM through Jun 2026 was 116.32, a N/A change from a year earlier, with the FY2025 full-year figure at 23.26, changed N/A from the prior year.
Price to Sales was 559.82 for Q2 2026 at Vyome Holdings, up from 477.66 in the prior quarter.
The five-year high for Price to Sales was 559.82 in Q2 2026, with the low at 203.41 in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Amgen	211.73 Bn	197.74 Bn	7.24 Bn
2	Gilead Sciences	180.92 Bn	177.74 Bn	6.22 Bn
3	Vertex Pharmaceuticals	132.16 Bn	124.30 Bn	2.84 Bn
4	Regeneron Pharmaceuticals	82.89 Bn	74.90 Bn	3.93 Bn
5	Argenx Se	61.41 Bn	56.23 Bn	1.37 Bn
6	Moderna	53.99 Bn	48.85 Bn	52.00 Mn
7	Alnylam Pharmaceuticals	34.48 Bn	31.18 Bn	992.69 Mn
8	Biogen	31.15 Bn	29.86 Bn	1.96 Bn
9	Roivant Sciences	30.05 Bn	30.05 Bn	1.16 Mn
10	Vyome Holdings	14.46 Mn	6.57 Mn	11,658.00

Historic Data

Download Data